P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON‐CELLULAR ANTI‐B‐CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY

• Published in: HemaSphere Vol. 7; no. S2; pp. 25 - 26
• Main Authors: Donk, N., Mateos, M.‐V., Cohen, Y.C., Rodriguez‐Otero, P., Paiva, B., Cohen, A.D., Martin, T., Suvannasankha, A., Madduri, D., Corsale, C., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Deraedt, W., Roccia, T., Mistry, P., Xu, X., Li, K., Zudaire, E., Akram, M., Pacaud, L., Avivi, I., San‐Miguel, J.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Lippincott Williams & Wilkins 09.05.2023; Wiley